These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 22952422)

  • 21. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
    Zeng Z; Samudio IJ; Munsell M; An J; Huang Z; Estey E; Andreeff M; Konopleva M
    Mol Cancer Ther; 2006 Dec; 5(12):3113-21. PubMed ID: 17172414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways.
    Huang CY; Lee CY; Chen MY; Yang WH; Chen YH; Chang CH; Hsu HC; Fong YC; Tang CH
    J Cell Physiol; 2009 Oct; 221(1):204-12. PubMed ID: 19496172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
    Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
    Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
    Zhu WB; Zhao ZF; Zhou X
    J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis.
    Song N; Huang Y; Shi H; Yuan S; Ding Y; Song X; Fu Y; Luo Y
    Cancer Res; 2009 Aug; 69(15):6057-64. PubMed ID: 19584297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.
    Teng F; Tian WY; Wang YM; Zhang YF; Guo F; Zhao J; Gao C; Xue FX
    J Hematol Oncol; 2016 Feb; 9():8. PubMed ID: 26851944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SDF-1α Promotes Chondrocyte Autophagy through CXCR4/mTOR Signaling Axis.
    Li J; Chen H; Cai L; Guo D; Zhang D; Zhou X; Xie J
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockade of SDF-1/CXCR4 reduces adhesion-mediated chemoresistance of multiple myeloma cells via interacting with interleukin-6.
    Liu Y; Liang HM; Lv YQ; Tang SM; Cheng P
    J Cell Physiol; 2019 Nov; 234(11):19702-19714. PubMed ID: 30953364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway.
    Zheng H; Fu G; Dai T; Huang H
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):274-80. PubMed ID: 17878755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
    Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
    Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
    Chiu CW; Nozawa H; Hanahan D
    J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SDF-1α/CXCR4 Signaling in Lipid Rafts Induces Platelet Aggregation via PI3 Kinase-Dependent Akt Phosphorylation.
    Ohtsuka H; Iguchi T; Hayashi M; Kaneda M; Iida K; Shimonaka M; Hara T; Arai M; Koike Y; Yamamoto N; Kasahara K
    PLoS One; 2017; 12(1):e0169609. PubMed ID: 28072855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory effects of Chanling Gao on the proliferation and liver metastasis of transplanted colorectal cancer in nude mice.
    Yang B; Pan CS; Li Q; Yang Z; Long FX; Fan JY; Wang CS; Han JY; Tang DX
    PLoS One; 2019; 14(2):e0201504. PubMed ID: 30789971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epitheloid carcinoma cells.
    Peng SB; Peek V; Zhai Y; Paul DC; Lou Q; Xia X; Eessalu T; Kohn W; Tang S
    Mol Cancer Res; 2005 Apr; 3(4):227-36. PubMed ID: 15831676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1α/CXCR4 paracrine signaling.
    Margolin DA; Silinsky J; Grimes C; Spencer N; Aycock M; Green H; Cordova J; Davis NK; Driscoll T; Li L
    Neoplasia; 2011 Sep; 13(9):874-86. PubMed ID: 21969820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
    Buck E; Eyzaguirre A; Haley JD; Gibson NW; Cagnoni P; Iwata KK
    Mol Cancer Ther; 2006 Aug; 5(8):2051-9. PubMed ID: 16928826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
    Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
    Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E; Eyzaguirre A; Brown E; Petti F; McCormack S; Haley JD; Iwata KK; Gibson NW; Griffin G
    Mol Cancer Ther; 2006 Nov; 5(11):2676-84. PubMed ID: 17121914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.